Kits for Prenatal Testing
The invention relates to a kit for prenatal testing comprising a size-based separation module which enriches a first cell type from a maternal blood sample found in vivo in a pregnant female at a concentration of less than 1% of all blood cells, and a set of instructions for analyzing said one or more enriched cells to make a prenatal diagnosis. In some embodiments, the size-based separation module can comprise a plurality of obstacles to selectively direct the one or more cells of the first cell type in a first direction away from one or more cells of a second cell type.
1 . A kit for prenatal testing comprising:
a size-based flow-through separation module adapted to isolate one or more cells of a first cell type from a maternal blood sample wherein said first cell type is found in vivo in a pregnant female at a concentration of less than 1% of all blood cells, and
a set of instructions for analyzing said one or more enriched cells to make a prenatal diagnosis of a fetus.
2 . The kit of claim 1 further comprising one or more reagents selected from the group consisting of: a PCR reagent, a lysis reagent, a nucleic acid probe, and a labeling reagent.
3 . The kit of claim 2 wherein said labeling reagent is a FISH reagent.
4 . The kit of claim 1 wherein said FISH reagent specifically binds a chromosome selected from the group consisting of X chromosome, Y chromosome, chromosome 13, chromosome 18, and chromosome 21.
5 . The kit of claim 1 further comprising a microarray.
6 . The kit of claim 1 wherein said size-based separation module comprises a two-dimensional array of obstacles that deterministically direct said one or more cells of a first cell type in a first direction and one or more cells of a second cell type in a second direction.
7 . The kit of claim 6 wherein said first cell type is a fetal cell.
8 . The kit of claim 6 wherein said second cell type is an enucleated red blood cell.
9 . The kit of claim 8 wherein said size-based separation module retains more than 99% of said first cell types and removes more than 99% of said enucleated red blood cells.
10 . The kit of claim 1 further comprising an array of obstacles, wherein said obstacles are coupled to an antibody is selected from the group consisting of an anti-CD71, anti-CD36, anti-selectin, anti-GPA, anti-CD45, and anti-antigen i.
11 . The kit of claim 1 wherein said prenatal diagnosis comprises determining sex of a fetus.
12 . The kit of claim 1 wherein said prenatal diagnosis comprises determining the existence trisomy 13, trisomy 18, trisomy 21 (Down's Syndrome), Turner Syndrome (damaged X chromosome), Klinefelter Syndrome (XXY) or another irregular number of sex or autosomal chromosomes.
13 . The kit of claim 1 wherein said prenatal diagnosis comprises determining a condition selected from the group consisting of: Wolf-Hirschhorn syndrome (4p-), Cri-du-chat (5p-), Williams syndrome (7q11.23), Prader-Willi syndrome (15q11.2-q13), Angelman syndrome (15q11.2-q13), Miller-Dieker syndrome (17p 13.3), Smith-Magenis syndrome (17p 11.2), DiGeorge and Velo-cardio-facial syndromes (22q11.2), Kallman syndrome (Xp22.3), Steroid Sulfatase Deficiency (STS) (Xp22.3), X-Linked Ichthiosis (Xp22.3), and Retinoblastoma (13q14).
14 . The kit of claim 1 wherein said separation module deterministically directs said first analyte in a first direction and a second analyte in a second direction.
15 . The kit of claim 1 wherein said separation module comprises one or more two dimensional arrays of obstacles that define a plurality of gaps that direct flow unequally into subsequent gaps.
16 . The kit of claim 1 wherein said prenatal diagnosis comprises determining sex of said fetus.
17 . The kit of claim 1 wherein said prenatal diagnosis comprises determining the existence of trisomy 13.